MRE11 and neoplasm: The present data aid in our understanding of this control process and further suggest that potential therapeutic approaches to trigger fusion in tumor cells with TRF2-containing dysfunctional telomeres (such as ALT-dependent tumors) will need to account for both MRE11 and UBR5 to be successful.